Intelligence · Clinical pipeline
Phase I Pipeline Programs
First-in-human and early clinical safety studies in Phase I.
Programs 56
Sponsors 800
Drugs 4,222
Quick answer
NovaPharmaNews tracks 56 phase i pharmaceutical pipeline programs from ClinicalTrials.gov. First-in-human and early clinical safety studies in Phase I.
Top sponsors
- BRIGHT MINDS BIOSCIENCES 327 programs
- Takeda 276 programs
- Anaxis Pharma 204 programs
- Chinese Academy of 190 programs
- United Therapeutics Europe 184 programs
- Teva Pharma 154 programs
- First People's Hospital 149 programs
- Regeneron UK 126 programs
- Boehringer Ingelheim 94 programs
- Sunshine Guojian Pharmaceutical 85 programs
- Lakefront Biotherapeutics NV 62 programs
- HOFFMANN-LA ROCHE 58 programs
Pipeline programs
-
TL011
Teva Pharma GmbH
DLBCL
1 trial -
TV44749-BA-10196
Lacuna Pharma Pty Ltd
Schizophrenia
1 trial -
The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)
Sinobioway Cell Therapy Co.,
Lymphoma
1 trial -
VHX-896 and iloperidone
Vanda Pharmaceuticals Netherlands B.V.
Schizophrenia
1 trial -
Ziftomenib
Kura Oncology
AML
1 trial -
anti-CD19 CAR NK
Chongqing Precision Biotech Co., Ltd
NHL
1 trial -
treatment A
United Therapeutics Europe Ltd
Dyslipidemia
1 trial -
ziv-aflibercept
Regeneron UK Limited
Lymphoma
2 trials
Frequently asked questions
How many Phase I pipeline programs are in the directory?
56 published programs match this development stage in our ClinicalTrials.gov index.
What defines this pipeline stage?
Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.